Applied Science Products, Inc. Announces Appointment of Dr. David Shulkin to Board
January 04 2011 - 10:05AM
Marketwired
Applied Science Products, Inc., (PINKSHEETS: APLD), is pleased to
announce the appointment of Dr. David Shulkin, President of
Morristown Memorial Hospital, a 642 bed comprehensive Medical
Center, and part of Atlantic Health Systems. Dr. Shulkin brings a
vast amount of experience and expertise in the healthcare area
enriching the company's plans for its plasma-based products in the
coming years.
In 2009 Dr. Shulkin was named one of the One Hundred Most
Influential People in American Healthcare by Modern Healthcare and
for the second year in a row was recognized among the "50 Most
Powerful Physician Executives in the Country" (ranked as #14 in
2009 and #12 in 2008) by Modern Healthcare and Modern Physician.
Previously, Dr. Shulkin was President and CEO of Beth Israel
Medical Center in New York. He has served in numerous physician
leadership roles including the Chief Medical Officer of the
University of Pennsylvania Health System, the Hospital of the
University of Pennsylvania, Temple University Hospital, and the
Medical College of Pennsylvania Hospital. Dr. Shulkin also served
in academic positions including the Chairman of Medicine and Vice
Dean at Drexel University School of Medicine.
Dr. Shulkin was also founder, Chairman and CEO of DoctorQuality,
Inc., one of the first consumer oriented sources of information for
quality and safety in healthcare. Dr. Shulkin has been on the
editorial boards of numerous journals including the Journal of the
American Medical Association and Hospital Physician, and is on the
editorial boards of the Journal of Safety, the Journal of Clinical
Outcomes Management and the Journal of Disease Mangement. Dr.
Shulkin is also widely published.
"We're very gratified to have Dr. Shulkin join our board," said
Kenneth Wood, CEO of Applied Science Products, Inc. "As a
recognized leader in his field, his experience, and entrepreneurial
background will be an invaluable asset in the development and
strategic marketing of our proprietary plasma-based technology,
especially since we have significant opportunity within the
healthcare market sector. We look forward to working with him."
Shulkin remarked, "I'm very pleased to join the Board of ASP. I
think the company's plasma technology is exciting and diverse in
application. Any time you can efficiently implement microbial
destruction technology into useful end products, you have
opportunity to address a number of problems facing the world
today."
Dr. Shulkin is a board certified internist, a fellow of the
American College of Physicians, Professor of Medicine at Albert
Einstein School of Medicine and a Senior Fellow at the Health
Research and Education Trust of the American Hospital Association,
a Senior Fellows at the School of Population Health at Thomas
Jefferson University, and a Senior Fellow (Adjunct) at the Leonard
Davis Institute in Health Economics at the University of
Pennsylvania.
Dr. Shulkin received his medical degree from the Medical College
of Pennsylvania, his internship at Yale University School of
Medicine, and a residency and Fellowship in General Medicine at the
University of Pittsburgh Presbyterian Medical Center. He received
advanced training in outcomes research and economics as a Robert
Wood Johnson Foundation Clinical Scholar at the University of
Pennsylvania.
Dr. Shulkin has received numerous awards and was named one of
the country's top Health care leaders for the next century by
Modern Healthcare, an international Leader in Health Care Award by
the Healthcare Forum.
About Advanced Plasma Products, Inc.
Advanced Plasma Products, Inc (APP) is a wholly owned subsidiary of
Applied Science Products, Inc. APP is a growth stage technology
company dedicated to developing and commercializing needed and
useful products based upon its patented platform One Atmosphere
Uniform Glow Discharge Plasma (OAUGDP) technology. APP's intent is
to leverage its unique atmospheric plasma technology into
development of a number of products in diverse, high growth
markets, such as healthcare, air purification, disinfection,
manufacturing, and biotechnology. The company has previously
released its TriClean Pro air purification product that includes
the company's newest advanced plasma design. The TriClean Pro is a
robust air sanitizer that effectively traps and destroys all known
classes of microorganisms such as pathogenic bacteria, viruses,
allergens and mold. It also removes odor-causing volatile organic
compounds (VOC's) providing a comprehensive approach to air
purification.
Safe Harbor statement under the Private
Securities Litigation Reform Act of 1995: This release contains
forward looking statements identified by the use of words such as
should, believes, plans, goals, expects, may, will, objectives,
missions, or the negative thereof, other variations thereon or
comparable terminology. Such statements are based on currently
available information which management has assessed but which is
dynamic and subject to rapid change due to risks and uncertainties
that affect our business such as the impact of competitive products
and pricing, limited visibility into future product demand, slower
economic growth generally, difficulties inherent in the development
of complex technology, new products sufficiency, availability of
capital to fund operations, research and development, fluctuations
in operating results, and other risks that may be identified and
detailed from time to time. Any statements that express or involve
discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, goals, assumptions or future events
or performance are not statements of historical fact and should be
considered forward looking statements. Forward looking statements
involve a number of risks and uncertainties which could cause
actual results or events to differ materially from those presently
anticipated.
Contact: Kenneth Wood Chief Executive Officer Applied
Science Products, Inc. (908) 507-6239